1. Parkinson J. An essay on the shaking palsy. 1817. J Neuropsychiatry Clin Neurosci. 2002;14(2):223–236. discussion 222. [PubMed]
2. von Campenhausen S, Bornschein B, Wick R, et al. Prevalence and incidence of Parkinson’s disease in Europe. Eur Neuropsychopharmacol. 2005;15(4):473–490.[PubMed]
3. Parkinson’s Disease Foundation [webpage on the internet] Parkinson’s Disease Foundation, Inc. updated ©2016. [Accessed January 2016]. Available from: http://www.pdf.org/en/parkinson_statistics.
4. Brooks DJ. Parkinson’s disease: diagnosis. Parkinsonism Relat Disord. 2012;18(suppl 1):S31–S33.[PubMed]
5. Negre-Pages L, Regragui W, Rascol O, DoPaMiP Study Group Chronic pain in Parkinson’s disease: the cross-sectional French DoPaMiP survey. Mov Disord. 2008;23(10):1361–1369.[PubMed]
6. Borg A, Borgman A. “Parkitouch”-studien, Parkinsons sjukdom och effekten av beröringsmassage [The Parkitouch Study: The effects of tactile touch in Parkinson’s disease] The Swedish Parkinson Foundation; 2009. [Accessed July 19, 2016]. Available from: http://www.parkinsonstiftelsen.se/parkitouch.html.
7. Bekkering GE, Bala MM, Reid K, et al. Epidemiology of chronic pain and its treatment in The Netherlands. Neth J Med. 2011;69(3):141–153.[PubMed]
8. Reid KJ, Harker J, Bala MM, et al. Epidemiology of chronic non-cancer pain in Europe: narrative review of prevalence, pain treatments and pain impact. Curr Med Res Opin. 2011;27(2):449–462.[PubMed]
9. Politis M, Wu K, Molloy S, G Bain P, Chaudhuri KR, Piccini P. Parkinson’s disease symptoms: the patient’s perspective. Mov Disord. 2010;25(11):1646–1651.[PubMed]
10. Schestatsky P, Kumru H, Valls-Solé J, et al. Neurophysiologic study of central pain in patients with Parkinson disease. Neurology. 2007;69(23):2162–2169.[PubMed]
11. Mylius V, Engau I, Teepker M, et al. Pain sensitivity and descending inhibition of pain in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2009;80(1):24–28.[PubMed]
12. Tison F, Wenning GK, Volonte MA, Poewe WR, Henry P, Quinn NP. Pain in multiple system atrophy. J Neurol. 1996;243(2):153–156.[PubMed]
13. Chudler EH, Dong WK. The role of the basal ganglia in nociception and pain. Pain. 1995;60(1):3–38.[PubMed]
14. Markus Z, Eordegh G, Paroczy Z, Benedek G, Nagy A. Modality distribution of sensory neurons in the feline caudate nucleus and the substantia nigra. Acta Biol Hung. 2008;59(3):269–279.[PubMed]
15. Baev KV. Disturbances of learning processes in the basal ganglia in the pathogenesis of Parkinson’s disease: a novel theory. Neurol Res. 1995;17(1):38–48.[PubMed]
16. Berger K, Przedborski S, Cadet JL. Retrograde degeneration of nigrostriatal neurons induced by intrastriatal 6-hydroxydopamine injection in rats. Brain Res Bull. 1991;26(2):301–307.[PubMed]
17. Le Moal M, Simon H. Mesocorticolimbic dopaminergic network: functional and regulatory roles. Physiol Rev. 1991;71(1):155–234.[PubMed]
18. Simon H, Le Moal M, Stinus L, Calas A. Anatomical relationships between the ventral mesencephalic tegmentum – a 10 region and the locus coeruleus as demonstrated by anterograde and retrograde tracing techniques. J Neural Transm. 1979;44(1–2):77–86.[PubMed]
19. Braz JM, Nassar MA, Wood JN, Basbaum AI. Parallel “pain” pathways arise from subpopulations of primary afferent nociceptor. Neuron. 2005;47(6):787–793.[PubMed]
20. Porro CA, Cavazzuti M, Baraldi P, Giuliani D, Panerai AE, Corazza R. CNS pattern of metabolic activity during tonic pain: evidence for modulation by beta-endorphin. Eur J Neurosci. 1999;11(3):874–888.[PubMed]
21. Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rub U. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson’s disease (preclinical and clinical stages) J Neurol. 2002;249(suppl 3):III, 1–5.[PubMed]
22. Gold A, Turkalp ZT, Munoz DG. Enteric alpha-synuclein expression is increased in Parkinson’s disease but not Alzheimer’s disease. Mov Disord. 2013;28(2):237–240.[PubMed]
23. Melzack R, Wall PD. Pain mechanisms: a new theory. Science. 1965;150(699):971–979.[PubMed]
24. Vallbo AB, Olausson H, Wessberg J. Unmyelinated afferents constitute a second system coding tactile stimuli of the human hairy skin. J Neurophysiol. 1999;81(6):2753–2763.[PubMed]
25. Skogar Ö, Borg A, Larsson B, et al. “Effects of tactile touch on pain, sleep and health related quality of life in Parkinson’s disease with chronic pain”: a randomized, controlled and prospective study. Eur J Integr Med. 2013;5(2):141–152.
26. Huskinson E. Visual analogue scale. In: Melzack R, editor. Measurement and Assessment. New York, NY: Raven Press; 1983.
27. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994;23(2):129–138.[PubMed]
28. Gaston-Johansson F. Measurement of pain: the psychometric properties of the Pain-O-Meter, a simple, inexpensive pain assessment tool that could change health care practices. J Pain Symptom Manage. 1996;12(3):172–181.[PubMed]
29. Chaudhuri KR, Rizos A, Trenkwalder C, et al. King’s Parkinson’s disease pain scale, the first scale for pain in PD: an international validation. Mov Disord. 2015;30(12):1623–1631.[PubMed]
30. Ford B. Pain in Parkinson’s disease. Clin Neurosci. 1998;5(2):63–72.[PubMed]
31. Jensen TS, Baron R, Haanpaa M, et al. A new definition of neuropathic pain. Pain. 2011;152(10):2204–2205.[PubMed]
32. Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70(18):1630–1635.[PubMed]
33. Snider SR, Fahn S, Cote LJ, Isgreen WP. Letter: pain, paresthesia and parkinsonism. N Engl J Med. 1975;293(4):200.[PubMed]
34. Stein WM, Read S. Chronic pain in the setting of Parkinson’s disease and depression. J Pain Symptom Manage. 1997;14(4):255–258.[PubMed]
35. Shang AB, King SA. Parkinson’s disease, depression, and chronic pain. Hosp Community Psychiatry. 1991;42(11):1162–1163.[PubMed]
36. King SA. Pain in depression and Parkinson’s disease. Am J Psychiatry. 1993;150(2):353–354.[PubMed]
37. Rana AQ, Depradine J. Abdominal pain: a symptom of levodopa end of dose wearing off in Parkinson’s disease. West Indian Med J. 2011;60(2):223–224.[PubMed]
38. Broetz D, Eichner M, Gasser T, Weller M, Steinbach JP. Radicular and nonradicular back pain in Parkinson’s disease: a controlled study. Mov Disord. 2007;22(6):853–856.[PubMed]
39. Kim YE, Jeon BS. Musculoskeletal problems in Parkinson’s disease. J Neural Transm (Vienna) 2013;120(4):537–542.[PubMed]
40. Storch A, Schneider CB, Wolz M, et al. Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology. 2013;80(9):800–809.[PubMed]
41. Rana AQ, Qureshi AR, Mumtaz A, et al. Associations of pain and depression with marital status in patients diagnosed with Parkinson’s disease. Acta Neurol Scand. 2016;133(4):276–280.[PubMed]
42. Rana AQ, Qureshi AR, Rahman L, Jesudasan A, Hafez KK, Rana MA. Association of restless legs syndrome, pain, and mood disorders in Parkinson’s disease. Int J Neurosci. 2016;126(2):116–120.[PubMed]
43. Ha AD, Jankovic J. Pain in Parkinson’s disease. Mov Disord. 2012;27(4):485–491.[PubMed]
44. Skogar O, Fall PA, Hallgren G, et al. Parkinson’s disease patients’ subjective descriptions of characteristics of chronic pain, sleeping patterns and health-related quality of life. Neuropsychiatr Dis Treat. 2012;8:435–442.[PMC free article][PubMed]
45. Trenkwalder C, Chaudhuri KR, Martinez-Martin P, et al. Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson’s disease (PANDA): a double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2015;14(12):1161–1170.[PubMed]
46. Tornhage CJ, Skogar O, Borg A, et al. Short- and long-term effects of tactile massage on salivary cortisol concentrations in Parkinson’s disease: a randomised controlled pilot study. BMC Complement Altern Med. 2013;13:357.[PMC free article][PubMed]
47. Jung YJ, Kim HJ, Jeon BS, Park H, Lee WW, Paek SH. An 8-year follow-up on the effect of subthalamic nucleus deep brain stimulation on pain in Parkinson Disease. JAMA Neurol. 2015;72(5):504–510.[PubMed]
48. Nishioka K, Nakajima M. Beneficial therapeutic effects of spinal cord stimulation in advanced cases of Parkinson’s Disease with intractable chronic pain: a case series. Neuromodulation. 2015;18(8):751–753.[PubMed]
49. Hunt KJ, Coelho HF, Wider B, et al. Complementary and alternative medicine use in England: results from a national survey. Int J Clin Pract. 2010;64(11):1496–1502.[PubMed]
50. Hanssen B, Grimsgaard S, Launso L, Fonnebo V, Falkenberg T, Rasmussen NK. Use of complementary and alternative medicine in the Scandinavian countries. Scand J Prim Health Care. 2005;23(1):57–62.[PubMed]
51. American Massage Therapy Association . AMTA Definition of Massage Therapy. Evanston, IL: AMTA; 2002. Retrieved August 27, 1999.
52. Tan YZ, Ozdemir S, Temiz A, Celik F. The effect of relaxing music on heart rate and heart rate variability during ECG GATED-myocardial perfusion scintigraphy. Complement Ther Clin Pract. 2015;21(2):137–140.[PubMed]
53. Pacchetti C, Mancini F, Aglieri R, Fundaro C, Martignoni E, Nappi G. Active music therapy in Parkinson’s disease: an integrative method for motor and emotional rehabilitation. Psychosom Med. 2000;62(3):386–393.[PubMed]
54. Liljeström S, Juslin PN, Västfjäll D. Experimental evidence of the roles of music choice, social context, and listener personality in emotional reactions to music. Psychol Music. 2012;41:579–599.
55. Cepeda MS, Carr DB, Lau J, Alvarez H. Music for pain relief. Cochrane Database Syst Rev. 2006;(2):CD004843.[PubMed]
56. Chan MF, Chan EA, Mok E. Effects of music on depression and sleep quality in elderly people: a randomised controlled trial. Complement Ther Med. 2010;18(3–4):150–159.[PubMed]
57. Melzack R, Wall PD. Pain mechanisms: a new theory. Science. 1965;150(699):971–979.[PubMed]
58. Field T, Diego M. Vagal activity, early growth and emotional development. Infant Behav Dev. 2008;31(3):361–373.[PMC free article][PubMed]
59. Field T, Hernandez-Reif M, Diego M, Schanberg S, Kuhn C. Cortisol decreases and serotonin and dopamine increase following massage therapy. Int J Neurosci. 2005;115(10):1397–1413.[PubMed]
60. Morhenn V, Beavin LE, Zak PJ. Massage increases oxytocin and reduces adrenocorticotropin hormone in humans. Altern Ther Health Med. 2012;18(6):11–18.[PubMed]
61. Boso M, Politi P, Barale F, Enzo E. Neurophysiology and neurobiology of the musical experience. Funct Neurol. 2006;21(4):187–191.[PubMed]
62. Menon V, Levitin DJ. The rewards of music listening: response and physiological connectivity of the mesolimbic system. Neuroimage. 2005;28(1):175–184.[PubMed]
63. Field TM. Massage therapy effects. Am Psychol. 1998;53(12):1270–1281.[PubMed]
64. Morhenn V, Beavin LE, Zak PJ. Massage increases oxytocin and reduces adrenocorticotropin hormone in humans. Altern Ther Health Med. 2012;18(6):11–18.[PubMed]
65. Zambito Marsala S, Tinazzi M, Vitaliani R, et al. Spontaneous pain, pain threshold, and pain tolerance in Parkinson’s disease. J Neurol. 2011;258(4):627–633.[PubMed
Dissertation fellowships will be awarded in a national competition administered by the National Academies of Sciences, Engineering, and Medicine on behalf of the Ford Foundation. The awards will be made to individuals who, in the judgment of the review panels, have demonstrated superior academic achievement, are committed to a career in teaching and research at the college or university level, show promise of future achievement as scholars and teachers, and are well prepared to use diversity as a resource for enriching the education of all students.
Click on the links below to learn more about each aspect of the Ford Foundation Dissertation Fellowship
In addition to the other dissertation program level requirements, eligibility to apply for a dissertation fellowship is limited to:
- All U.S. citizens, U.S. nationals, and U.S. permanent residents (holders of a Permanent Resident Card), as well as individuals granted deferred action status under the Deferred Action for Childhood Arrivals Program, political asylees, and refugees, regardless of race, national origin, religion, gender, age, disability, or sexual orientation,
- Individuals with evidence of superior academic achievement (such as grade point average, class rank, honors, or other designations),
- Individuals committed to a career in teaching and research at the college or university level,
- Ph.D. or Sc.D. degree candidates studying in an eligible research-based discipline in a dissertation-required program at a non-proprietary (not for profit) U.S. institution of higher education who will complete the dissertation in a period of 9-12 months during the 2018-2019 academic year, and
- Individuals who have not earned a doctoral degree at any time, in any field.
Criteria for Selection
- Evidence of superior academic achievement
- Degree of promise of continuing achievement as scholars and teachers
- Capacity to respond in pedagogically productive ways to the learning needs of students from diverse backgrounds
- Sustained personal engagement with communities that are underrepresented in the academy and an ability to bring this asset to learning, teaching, and scholarship at the college and university level
- Likelihood of using the diversity of human experience as an educational resource in teaching and scholarship
- Membership in one or more of the following groups whose underrepresentation in the American professoriate has been severe and longstanding:
- Alaska Natives (Aleut, Eskimo, or other Indigenous People of Alaska)
- Black/African Americans
- Mexican Americans/Chicanas/Chicanos
- Native American Indians
- Native Pacific Islanders (Hawaiian/Polynesian/Micronesian)
- Puerto Ricans
Applications will be evaluated by panels of distinguished scholars selected by the National Academies. The panels will use academic records, essays, letters of recommendation, the application itself, and other appropriate materials as the basis for determining the extent to which candidates meet the eligibility requirements and the selection criteria. Review panels may also look at additional factors such as whether the applicant has advanced to dissertation candidacy and will fully utilize 9 to 12 months of fellowship support prior to receiving the Ph.D. or Sc.D.
To the Top
Eligible Fields of Study
Awards will be made for study in research-based Ph.D. or Sc.D. programs that include the following major disciplines and related interdisciplinary fields: American studies, anthropology, archaeology, art and theater history, astronomy, chemistry, communications, computer science, cultural studies, earth sciences, economics, education, engineering, ethnic studies, ethnomusicology, geography, history, international relations, language, life sciences, linguistics, literature, mathematics, performance study, philosophy, physics, political science, psychology, religious studies, sociology, urban planning, and women’s studies. Also eligible are interdisciplinary ethnic studies programs, such as African American studies and Native American studies, and other interdisciplinary programs, such as area studies, peace studies, and social justice. Research-based fields of education are eligible if the major field of study is listed above and is used to describe the Ph.D. or Sc.D. program of the applicant (e.g., sociology of education, anthropology and education).
The complete list of eligible fields of study supported at the dissertation level of the fellowship program is available here: Eligible Fields of Study List.
Individuals enrolled in the following practice-oriented programs will not be supported: administration, audiology, business, consumer studies, curriculum development, human resource management, exercise physiology, filmmaking, fine arts, guidance, kinesiology, leadership, library and information science, management, nursing, occupational health, performing arts, personnel, physical education, physical therapy, public health, rehabilitation science, social welfare, social work, speech pathology, and teacher education. In addition, awards will not be made for work leading to terminal master’s degrees, the Ed.D. degree, the degrees of Doctor of Fine Arts (D.F.A.) or Doctor of Psychology (Psy.D.), or professional degrees in such areas as medicine, law, and public health, or for study in joint degree programs such as the M.D./Ph.D., J.D./Ph.D., and M.F.A./Ph.D. This program does not support the Ph.D. portion of a dual-degree program. Interdisciplinary areas of study that have major content in ineligible fields listed above will not be included in the competition.
To the Top
Verification of Doctoral Degree Status
- In order to compete, applicants must have successfully achieved doctoral degree candidacy as defined by this program: applicants must have completed all departmental and institutional requirements for their degree, except for writing and defense of the dissertation. These requirements include, for example, required course work, language requirements, admission to doctoral candidacy, and approval of the dissertation proposal. A valid Academies Verification of Doctoral Degree Status Form, signed by the adviser or other authorized official, must be uploaded to the online fellowship application before 5:00 PM ET on January 9, 2018 to confirm that an applicant has advanced to doctoral candidacy.
- Applicants should expect to complete the dissertation during the 2018-2019 academic year.
Stipend and Benefits
To the Top
Conditions of the Fellowship
To the Top